CareDx Inc
NASDAQ:CDNA

Watchlist Manager
CareDx Inc Logo
CareDx Inc
NASDAQ:CDNA
Watchlist
Price: 23.13 USD 2.44% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
CareDx Inc?
Write Note

CareDx Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CareDx Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
CareDx Inc
NASDAQ:CDNA
Capital Expenditures
-$6.6m
CAGR 3-Years
24%
CAGR 5-Years
-16%
CAGR 10-Years
-33%
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$888m
CAGR 3-Years
0%
CAGR 5-Years
-12%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$974m
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$508.9m
CAGR 3-Years
-32%
CAGR 5-Years
-47%
CAGR 10-Years
-26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$928.1m
CAGR 3-Years
-18%
CAGR 5-Years
-20%
CAGR 10-Years
-13%
No Stocks Found

CareDx Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in South San Francisco, California and currently employs 633 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The firm offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products include AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. The company develops and provides diagnostic surveillance testing services for various transplant recipients.

CDNA Intrinsic Value
16.9 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is CareDx Inc's Capital Expenditures?
Capital Expenditures
-6.6m USD

Based on the financial report for Sep 30, 2024, CareDx Inc's Capital Expenditures amounts to -6.6m USD.

What is CareDx Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-33%

Over the last year, the Capital Expenditures growth was 40%. The average annual Capital Expenditures growth rates for CareDx Inc have been 24% over the past three years , -16% over the past five years , and -33% over the past ten years .

Back to Top